Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.

This publication has 10 references indexed in Scilit:

• Diurnal variation of plasma protease inhibitor concentrations
  AIDS, 2002
• Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography
  Journal of Chromatography B, 2002
• High Indinavir Cmin Is Associated With Higher Toxicity in Patients on Indinavir-Ritonavir 800/100 mg Twice-Daily Regimen
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Long‐term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
  HIV Medicine, 2002
• A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Therapeutic drug monitoring as a tool in treating HIV infection
  AIDS, 2001
• 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
  Annals of Internal Medicine, 2000
• The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
  AIDS, 1999
• A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
  New England Journal of Medicine, 1997
• Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
  Annals of Internal Medicine, 1997